Sample collection and testing
PD‐L1
BLOOD, APPENDIX, DISEASE PROGRESSION
For all patients, 8–10 mL of peripheral blood was collected dynamically and preserved in EDTA anticoagulated tubes. Blood samples were taken at the following times before treatment, at the time of each efficacy evaluation and after disease progression. Next generation sequencing (NGS) was performed on the blood samples collected at baseline, efficacy evaluation, and disease progression; TMB was calculated; and plasma PD‐L1 expression was determined by MSD (more details see Appendix 